These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 1489581)

  • 21. Synthetic peptides from a conserved region of gp120 induce broadly reactive anti-HIV responses.
    Morrow WJ; Williams WM; Whalley AS; Ryskamp T; Newman R; Kang CY; Chamat S; Köhler H; Kieber-Emmons T
    Immunology; 1992 Apr; 75(4):557-64. PubMed ID: 1592430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic.
    Zhang W; Canziani G; Plugariu C; Wyatt R; Sodroski J; Sweet R; Kwong P; Hendrickson W; Chaiken I
    Biochemistry; 1999 Jul; 38(29):9405-16. PubMed ID: 10413516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a phosphodiester hexanucleotide that inhibits HIV-1 infection in vitro on covalent linkage of its 5'-end with a dimethoxytrityl residue.
    Furukawa H; Momota K; Agatsuma T; Yamamoto I; Kimura S; Shimada K
    Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):167-75. PubMed ID: 9212907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergism between HIV gp120 and gp120-specific antibody in blocking human T cell activation.
    Mittler RS; Hoffmann MK
    Science; 1989 Sep; 245(4924):1380-2. PubMed ID: 2571187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects on CD4 binding of anti-peptide sera to the fourth and fifth conserved domains of HIV-1 gp120.
    Ardman B; Kowalski M; Bristol J; Haseltine W; Sodroski J
    J Acquir Immune Defic Syndr (1988); 1990; 3(3):206-14. PubMed ID: 2304000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Backbone and C beta assignments of the anti-gp120 antibody Fv fragment complexed with an antigenic peptide.
    Tugarinov V; Levy R; Dahan-Schokoroy A; Anglister J
    J Biomol NMR; 1999 Feb; 13(2):193-4. PubMed ID: 10070760
    [No Abstract]   [Full Text] [Related]  

  • 27. Inhibition of serum-enhanced HIV-1 infection of U937 monocytoid cells by recombinant soluble CD4 and anti-CD4 monoclonal antibody.
    Zeira M; Byrn RA; Groopman JE
    AIDS Res Hum Retroviruses; 1990 May; 6(5):629-39. PubMed ID: 2361075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Diagnosis and the methods of evaluating the degree of impairment of the immune system in HIV infection].
    Radkowski M; Laskus T
    Pol Arch Med Wewn; 1992 Jun; 87(6):372-8. PubMed ID: 1357632
    [No Abstract]   [Full Text] [Related]  

  • 29. Infection of human T cells with mycoplasma, inhibition of CD4 expression and HIV-1 gp120 glycoprotein binding, and infectivity.
    O'Toole C; Lowdell M
    Lancet; 1990 Oct; 336(8722):1067. PubMed ID: 1977037
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunological characteristics of the putative CD4-binding site of the HIV-1 envelope protein.
    Kieber-Emmons T; Krowka JF; Boyer J; Ugen KE; Williams WV; Morrow WJ; Weiner DB
    Pathobiology; 1992; 60(4):187-94. PubMed ID: 1388715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mimicking ligands.
    Heng JE; Dreyer EB
    Nature; 1993 Jan; 361(6409):211; author reply 212. PubMed ID: 8423847
    [No Abstract]   [Full Text] [Related]  

  • 32. Gp120 activates children's brain endothelial cells via CD4.
    Stins MF; Shen Y; Huang SH; Gilles F; Kalra VK; Kim KS
    J Neurovirol; 2001 Apr; 7(2):125-34. PubMed ID: 11517385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apoptosis in AIDS.
    Gougeon ML; Montagnier L
    Science; 1993 May; 260(5112):1269-70. PubMed ID: 8098552
    [No Abstract]   [Full Text] [Related]  

  • 34. Further insights on the inhibition of HIV type 1 infection in vitro by CD4-modified synthetic peptides containing phenylalanine.
    Prieto I; Lasarte JJ; Sarobe P; Golvano J; Civeira MP; Gullón A; Prieto J; Borrás-Cuesta F
    AIDS Res Hum Retroviruses; 1996 Jul; 12(11):1023-30. PubMed ID: 8827218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SPC 3.
    Drugs R D; 1999 Nov; 2(5):352. PubMed ID: 10728480
    [No Abstract]   [Full Text] [Related]  

  • 36. The natural history of human immunodeficiency virus infection in screened HIV positive U.S. Air Force personnel: a preliminary report.
    Reid MJ; Goetz DW; Zajac RA; Houk RW; Boswell RN
    J Acquir Immune Defic Syndr (1988); 1988; 1(5):508-15. PubMed ID: 3221323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new use for intracellular antibody expression: inactivation of human immunodeficiency virus type 1.
    Carlson JR
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7427-8. PubMed ID: 8356037
    [No Abstract]   [Full Text] [Related]  

  • 38. HIV-1-induced immune suppression may result from autoimmune disorders including anti-SLWDQ autoantibodies.
    Zagury JF; Bernard J; Achour A; Astgen A; Lachgar A; Fall L; Carelli C; Issing W; Mbika JP; Cantalloube H
    Biomed Pharmacother; 1993; 47(2-3):93-9. PubMed ID: 8218954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD26 and HIV infection.
    Callebaut C; Hovanessian AG
    Res Virol; 1996; 147(1):67-9. PubMed ID: 8882342
    [No Abstract]   [Full Text] [Related]  

  • 40. Antibodies to an HIV-1 synthetic peptide with partial homology to MULV P15E do not protect against AIDS.
    Lange J; Vahlne A; Dekker J; de Wolf F; Goudsmit J
    AIDS; 1989 Jun; 3(6):402-3. PubMed ID: 2502156
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.